Skip to main content
Top
Published in: Discover Oncology 2/2010

01-04-2010

The Role of Sex Steroid Receptors on Lipogenesis in Breast and Prostate Carcinogenesis: A Viewpoint

Authors: Henri Rochefort, Dany Chalbos

Published in: Discover Oncology | Issue 2/2010

Login to get access

Abstract

Cancer cells require both nutrients and mitogens to multiply and survive in the unfavorable microenvironment of solid tumors or metastases before angiogenesis. Most cancer cells do not use fatty acids (FA) from the circulation but synthesize them in situ especially to make membranes and lipid signals required for continuously dividing cells. Three lipogenic enzymes are overexpressed, induced by sex steroid hormones and responsible for the in situ increased lipogenesis in cancer cells. We propose that in the early stages of human breast and prostate carcinogenesis, an increased activity of sex steroid receptors is partly responsible for the overexpression of FA synthase (FASN) whose regulation in cancer cells has been particularly studied. Increased activity of androgen receptor (AR), via different mechanisms, was extensively reported in prostate cancer. An increased level/and or activity of progesterone receptors, correlated with an increased expression of FASN, was found both in early stages of breast carcinogenesis and during the hormone replacement therapy of menopausal women. While the majority of recent targeted therapies are based on inhibition of mitogenic pathways, the inhibition of cancer cell nutrition by interfering with lipid synthesis and hormone action should open the way to new therapeutic and preventive approaches of hormone-dependent cancers.
Literature
1.
go back to reference Mangelsdorf DJ, Thummel C, Beato M et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839CrossRefPubMed Mangelsdorf DJ, Thummel C, Beato M et al (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839CrossRefPubMed
2.
go back to reference Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333CrossRef Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333CrossRef
3.
go back to reference Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Current Opin Clin Nutr Metab Care 9:358–365CrossRef Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Current Opin Clin Nutr Metab Care 9:358–365CrossRef
4.
go back to reference Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763–777CrossRefPubMed Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763–777CrossRefPubMed
5.
go back to reference DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: metabolism and tumor cell growth. Current Opinion in Genetics and Development 18:54–61CrossRefPubMed DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: metabolism and tumor cell growth. Current Opinion in Genetics and Development 18:54–61CrossRefPubMed
6.
go back to reference Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis. Nature Reviews Cancer 4:891–899CrossRefPubMed Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis. Nature Reviews Cancer 4:891–899CrossRefPubMed
7.
go back to reference Wakil S (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523–4530CrossRefPubMed Wakil S (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28:4523–4530CrossRefPubMed
8.
go back to reference Weiss L, Hoffmann GE, Schreiber R et al (1986) Fatty-acid biosynthesis in man, a pathway of minor importance. Biol Chem Hoppe-Seyler 367:905–912PubMed Weiss L, Hoffmann GE, Schreiber R et al (1986) Fatty-acid biosynthesis in man, a pathway of minor importance. Biol Chem Hoppe-Seyler 367:905–912PubMed
9.
go back to reference Anderson SM, Rudolph MC, Mc Manaman JL et al (2007) Key stages in mammary gland development. Secretory activation in the mammary gland: it’s not just about milk protein synthesis! Breast Cancer Res 9:204–210CrossRefPubMed Anderson SM, Rudolph MC, Mc Manaman JL et al (2007) Key stages in mammary gland development. Secretory activation in the mammary gland: it’s not just about milk protein synthesis! Breast Cancer Res 9:204–210CrossRefPubMed
10.
go back to reference Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R (2004) Overexpression and hyperactivity of breast cancer associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues. Int J Oncol 24:1369–83PubMed Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R (2004) Overexpression and hyperactivity of breast cancer associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues. Int J Oncol 24:1369–83PubMed
11.
go back to reference Little JL, Kridel SJ (2008) Fatty acid synthase activity in tumor cells. Subcell Biochem 49:169–94 (review)CrossRefPubMed Little JL, Kridel SJ (2008) Fatty acid synthase activity in tumor cells. Subcell Biochem 49:169–94 (review)CrossRefPubMed
12.
go back to reference Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Review Cancer 8:705–713CrossRef Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Review Cancer 8:705–713CrossRef
13.
go back to reference Furuta E, Pai SK, Zhan R et al (2008) Fatty acid is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Research 68:1003–1111CrossRefPubMed Furuta E, Pai SK, Zhan R et al (2008) Fatty acid is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Research 68:1003–1111CrossRefPubMed
14.
go back to reference Moncur JT, Park JP, Memoli VA, Mohandas TK, Kinlaw WB (1998) The “Spot 14” gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: implications for control of tumor metabolism. Proc Natl Acad Sci USA 95:6989–6994CrossRefPubMed Moncur JT, Park JP, Memoli VA, Mohandas TK, Kinlaw WB (1998) The “Spot 14” gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: implications for control of tumor metabolism. Proc Natl Acad Sci USA 95:6989–6994CrossRefPubMed
15.
go back to reference Sinilnikova OM, Ginolhac SM, Magnard C et al (2004) Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 25:2417–2424CrossRefPubMed Sinilnikova OM, Ginolhac SM, Magnard C et al (2004) Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 25:2417–2424CrossRefPubMed
16.
go back to reference Moreau K, Dizin E, Ray H, Luquain C, Lefai E et al (2006) BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281:3172–3181CrossRefPubMed Moreau K, Dizin E, Ray H, Luquain C, Lefai E et al (2006) BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281:3172–3181CrossRefPubMed
17.
go back to reference Chalbos D, Chambon M, Ailhaud G et al (1987) Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262:9923–9926PubMed Chalbos D, Chambon M, Ailhaud G et al (1987) Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262:9923–9926PubMed
18.
go back to reference Rochefort H, Chalbos D (1984) Progestin specific markers in human cell lines: biological and pharmacological applications. Mol Cell Endocrinol 36:3–10CrossRefPubMed Rochefort H, Chalbos D (1984) Progestin specific markers in human cell lines: biological and pharmacological applications. Mol Cell Endocrinol 36:3–10CrossRefPubMed
19.
go back to reference Joyeux C, Rochefort H, Chalbos D (1989) Progestin increases gene transcription and messenger ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol Endocrinol 4:681–686CrossRef Joyeux C, Rochefort H, Chalbos D (1989) Progestin increases gene transcription and messenger ribonucleic acid stability of fatty acid synthetase in breast cancer cells. Mol Endocrinol 4:681–686CrossRef
20.
go back to reference Amy CM, Williams-Ahlf B, Naggert J, Smith S (1990) Molecular cloning of the mammalian fatty acid synthase gene and identification of the promoter region. Biochem J 271:675–679PubMed Amy CM, Williams-Ahlf B, Naggert J, Smith S (1990) Molecular cloning of the mammalian fatty acid synthase gene and identification of the promoter region. Biochem J 271:675–679PubMed
21.
go back to reference Rolland V, Liepvre XL, Jump DB, Lavau M, Dugail IA (1996) GC-rich region containing Sp1 and Sp1-like binding sites is a crucial regulatory motif for fatty acid synthase gene promoter activity in adipocytes. Implication in the overactivity of FAS promoter in obese Zucker rats. J Biol Chem 271:21297–212302CrossRefPubMed Rolland V, Liepvre XL, Jump DB, Lavau M, Dugail IA (1996) GC-rich region containing Sp1 and Sp1-like binding sites is a crucial regulatory motif for fatty acid synthase gene promoter activity in adipocytes. Implication in the overactivity of FAS promoter in obese Zucker rats. J Biol Chem 271:21297–212302CrossRefPubMed
22.
go back to reference Yang YA, Morin PJ, Han WF et al (2002) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132–137CrossRef Yang YA, Morin PJ, Han WF et al (2002) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132–137CrossRef
23.
go back to reference Chalbos D, Escot C, Joyeux C et al (1990) Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridisation. J Natl Cancer Inst 82:602–606CrossRefPubMed Chalbos D, Escot C, Joyeux C et al (1990) Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridisation. J Natl Cancer Inst 82:602–606CrossRefPubMed
24.
go back to reference Joyeux C, Chalbos D, Rochefort H (1990) Effects of progestins and menstrual cycle on fatty acid synthetase and progesterone receptor in human mammary glands. J Clin Endocrinol Metab 70:1438–1444CrossRefPubMed Joyeux C, Chalbos D, Rochefort H (1990) Effects of progestins and menstrual cycle on fatty acid synthetase and progesterone receptor in human mammary glands. J Clin Endocrinol Metab 70:1438–1444CrossRefPubMed
25.
go back to reference Escot C, Joyeux C, Mathieu M, Maudelonde T, Pages A, Rochefort H, Chalbos D (1990) Regulation of fatty acid synthetase ribonucleic acid in the human endometrium during the menstrual cycle. J Clin Endocrinol Metab 70:1319–1324CrossRefPubMed Escot C, Joyeux C, Mathieu M, Maudelonde T, Pages A, Rochefort H, Chalbos D (1990) Regulation of fatty acid synthetase ribonucleic acid in the human endometrium during the menstrual cycle. J Clin Endocrinol Metab 70:1319–1324CrossRefPubMed
26.
go back to reference Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454CrossRefPubMed Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114:448–454CrossRefPubMed
27.
go back to reference Alo PL, Visca P, Marci A et al (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474–482CrossRefPubMed Alo PL, Visca P, Marci A et al (1996) Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77:474–482CrossRefPubMed
28.
go back to reference Kuhajda FP, Piantadosi S, Pasternack GR (1989) Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636–641PubMedCrossRef Kuhajda FP, Piantadosi S, Pasternack GR (1989) Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636–641PubMedCrossRef
29.
go back to reference Heemers HV, Verhoeven G, Swinnen JV (2006) Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol 20:2265–2277CrossRefPubMed Heemers HV, Verhoeven G, Swinnen JV (2006) Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol 20:2265–2277CrossRefPubMed
30.
go back to reference Edgard G, Tang D, Rossi S et al (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5:253–261CrossRef Edgard G, Tang D, Rossi S et al (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5:253–261CrossRef
31.
go back to reference Fajas L, Debril MB, Auwerx J (2001) Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1–9CrossRefPubMed Fajas L, Debril MB, Auwerx J (2001) Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1–9CrossRefPubMed
32.
go back to reference Hisatake JI, Ikezoe T, Carey M et al (2000) Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60:5494–5498PubMed Hisatake JI, Ikezoe T, Carey M et al (2000) Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60:5494–5498PubMed
33.
go back to reference Qiao S, Pennanen P, Nazarova N, Lou YR, Tuohimaa P (2003) Inhibition of fatty acid synthase expression by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol 85:1–8CrossRefPubMed Qiao S, Pennanen P, Nazarova N, Lou YR, Tuohimaa P (2003) Inhibition of fatty acid synthase expression by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol 85:1–8CrossRefPubMed
34.
go back to reference Buchanan G, Irvine RA, Coetzee GA, Tilley WD (2001) Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20:207–223CrossRefPubMed Buchanan G, Irvine RA, Coetzee GA, Tilley WD (2001) Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 20:207–223CrossRefPubMed
35.
go back to reference Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98(1):19–22CrossRefPubMed Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98(1):19–22CrossRefPubMed
36.
go back to reference Leav I, McNeal JE, Kwan PW, Komminoth P, Merk FB (1996) Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate 29:137–145CrossRefPubMed Leav I, McNeal JE, Kwan PW, Komminoth P, Merk FB (1996) Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate 29:137–145CrossRefPubMed
37.
go back to reference Endogenous Sex Hormones and Prostate Cancer Collaborative Group (2008) A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170–183CrossRef Endogenous Sex Hormones and Prostate Cancer Collaborative Group (2008) A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100:170–183CrossRef
38.
go back to reference Gottlieb B et al (2004) The androgen receptor gene mutations database (ARDB). Hum Mutat 23:527–533CrossRefPubMed Gottlieb B et al (2004) The androgen receptor gene mutations database (ARDB). Hum Mutat 23:527–533CrossRefPubMed
39.
go back to reference Lange EM et al (2008) The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men’s Health Study. J Hum Genet 53:220–226CrossRefPubMed Lange EM et al (2008) The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men’s Health Study. J Hum Genet 53:220–226CrossRefPubMed
40.
go back to reference Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778–808CrossRefPubMed Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778–808CrossRefPubMed
41.
go back to reference Karpf AR, Bai S, James SR, Mohler JL, Wilson EM (2009) Increased expression of androgen receptor coregulator; MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 7:523–535CrossRefPubMed Karpf AR, Bai S, James SR, Mohler JL, Wilson EM (2009) Increased expression of androgen receptor coregulator; MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 7:523–535CrossRefPubMed
42.
go back to reference Edwards J, Krishna NS, Grigor KM, Bartlett JMS (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552–556CrossRefPubMed Edwards J, Krishna NS, Grigor KM, Bartlett JMS (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552–556CrossRefPubMed
43.
go back to reference Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22):1687–97CrossRefPubMed Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22):1687–97CrossRefPubMed
44.
go back to reference Rochefort H, Sahla M, Chalbos D (2005) Progestins-induced genes and breast cancer risk: good or bad? In: Li JJ (ed) Hormonal carcinogenesis, vol 4. Springer, New York, pp 65–76CrossRef Rochefort H, Sahla M, Chalbos D (2005) Progestins-induced genes and breast cancer risk: good or bad? In: Li JJ (ed) Hormonal carcinogenesis, vol 4. Springer, New York, pp 65–76CrossRef
45.
go back to reference Vignon F, Bardon S, Chalbos D, Rochefort H (1983) Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrin Metab 56:1124–1130CrossRef Vignon F, Bardon S, Chalbos D, Rochefort H (1983) Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrin Metab 56:1124–1130CrossRef
46.
go back to reference Chambon M, Rochefort H, Vial HJ et al (1989) Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors. J Steroid Biochem 33:915–922CrossRefPubMed Chambon M, Rochefort H, Vial HJ et al (1989) Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors. J Steroid Biochem 33:915–922CrossRefPubMed
47.
go back to reference Graham JD, Mote PA, Salagame U, van Dijk JH et al (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 50:3318–3326CrossRef Graham JD, Mote PA, Salagame U, van Dijk JH et al (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 50:3318–3326CrossRef
48.
go back to reference Beral V, the MWS group (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRefPubMed Beral V, the MWS group (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427CrossRefPubMed
49.
go back to reference Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA (1998) A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A 95:5076–5081CrossRefPubMed Brisken C, Park S, Vass T, Lydon JP, O'Malley BW, Weinberg RA (1998) A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc Natl Acad Sci U S A 95:5076–5081CrossRefPubMed
50.
go back to reference Hyder SM, Chiappetta C, Stancel GM (2001) Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 92:469–473CrossRefPubMed Hyder SM, Chiappetta C, Stancel GM (2001) Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 92:469–473CrossRefPubMed
51.
go back to reference Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93:3295–3298CrossRefPubMed Horwitz KB, Sartorius CA (2008) Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 93:3295–3298CrossRefPubMed
52.
go back to reference Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H (2007) Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer 120(2):224–229CrossRefPubMed Esslimani-Sahla M, Thezenas S, Simony-Lafontaine J, Kramar A, Lavaill R, Chalbos D, Rochefort H (2007) Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer 120(2):224–229CrossRefPubMed
53.
go back to reference Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80–90CrossRefPubMed Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80–90CrossRefPubMed
54.
go back to reference Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM (2003) Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63(1):132–139PubMed Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM (2003) Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63(1):132–139PubMed
55.
go back to reference Anzick S et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968CrossRefPubMed Anzick S et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968CrossRefPubMed
56.
go back to reference Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL (2005) Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 19:2713–2735CrossRefPubMed Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL (2005) Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 19:2713–2735CrossRefPubMed
57.
go back to reference Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM (2009) Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Mol Endocrinol 23:1135–1146CrossRefPubMed Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM (2009) Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Mol Endocrinol 23:1135–1146CrossRefPubMed
58.
go back to reference Chalbos D, Haagensen D, Parish T et al (1987) Identification and androgen regulation of two proteins released by the T47D human breast cancer cells. Cancer Res 47:2782–2792 Chalbos D, Haagensen D, Parish T et al (1987) Identification and androgen regulation of two proteins released by the T47D human breast cancer cells. Cancer Res 47:2782–2792
59.
go back to reference Bao Y, Hunter L, Jenkins JR et al (2005) Zn_alpha2-glycoprotein, a lipid mobilizing factor is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579:41–47CrossRefPubMed Bao Y, Hunter L, Jenkins JR et al (2005) Zn_alpha2-glycoprotein, a lipid mobilizing factor is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579:41–47CrossRefPubMed
60.
go back to reference Farmer P, Bonnefoi H, Becette V et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660–4671CrossRefPubMed Farmer P, Bonnefoi H, Becette V et al (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660–4671CrossRefPubMed
61.
go back to reference Chirala SS, Chang H, Matzuk M et al (2003) Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci USA 100:6358–6363CrossRefPubMed Chirala SS, Chang H, Matzuk M et al (2003) Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci USA 100:6358–6363CrossRefPubMed
62.
63.
go back to reference Fiorentino M, Zadra G, Palescandolo M et al (2008) Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 88:1340–1348CrossRefPubMed Fiorentino M, Zadra G, Palescandolo M et al (2008) Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 88:1340–1348CrossRefPubMed
64.
go back to reference Rossi S, Graner E, Febbo P, Weinstein L et al (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707–715PubMed Rossi S, Graner E, Febbo P, Weinstein L et al (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1:707–715PubMed
65.
go back to reference Kuhajda FP, Jenner K, Wood FD et al (1994) Fatty acid synthase: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379–6383CrossRefPubMed Kuhajda FP, Jenner K, Wood FD et al (1994) Fatty acid synthase: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379–6383CrossRefPubMed
66.
go back to reference Baron A, Migita T, Tang D et al (2004) Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91:47–53CrossRefPubMed Baron A, Migita T, Tang D et al (2004) Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91:47–53CrossRefPubMed
67.
go back to reference Puig T, Turrado C, Benhamú B, Aguilar H et al (2009) Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 15:7608–7615CrossRefPubMed Puig T, Turrado C, Benhamú B, Aguilar H et al (2009) Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 15:7608–7615CrossRefPubMed
68.
go back to reference Little JL, Wheeler FB, Koumenis C, Kridel SJ (2008) Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death. Mol Cancer Ther 7:3816–3824CrossRefPubMed Little JL, Wheeler FB, Koumenis C, Kridel SJ (2008) Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death. Mol Cancer Ther 7:3816–3824CrossRefPubMed
69.
go back to reference Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY (2006) Prevention of BrCa1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467–1470CrossRefPubMed Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY (2006) Prevention of BrCa1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467–1470CrossRefPubMed
70.
go back to reference Smith MR, Manola J, Kaufman DS et al (2004) Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101:1569–1574CrossRefPubMed Smith MR, Manola J, Kaufman DS et al (2004) Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101:1569–1574CrossRefPubMed
71.
go back to reference Annicotte JS, Iankova I, Miard S et al (2006) Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26:7561–7574CrossRefPubMed Annicotte JS, Iankova I, Miard S et al (2006) Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26:7561–7574CrossRefPubMed
72.
go back to reference Tian WX (2006) Inhibition of fatty acid synthase by polyphenols. Curr Med Chem 13(8):967–77 (review)CrossRefPubMed Tian WX (2006) Inhibition of fatty acid synthase by polyphenols. Curr Med Chem 13(8):967–77 (review)CrossRefPubMed
73.
go back to reference Khan N, Asim M, Afaq F, Abu Zaid M, Mukhtar H (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 68:8555–8563CrossRefPubMed Khan N, Asim M, Afaq F, Abu Zaid M, Mukhtar H (2008) A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 68:8555–8563CrossRefPubMed
74.
go back to reference Shin ES, Lee HH, Cho SY et al (2007) Genistein down regulates SREBP-1 regulated gene expression by inhibiting site-1 protease expression in HepG2 cells. J Nutr 137:1127–1131PubMed Shin ES, Lee HH, Cho SY et al (2007) Genistein down regulates SREBP-1 regulated gene expression by inhibiting site-1 protease expression in HepG2 cells. J Nutr 137:1127–1131PubMed
75.
go back to reference Dang C-C, Audinot V, Papapoulos SE, Boutin JA, Löwik CWGM (2003) Peroxisome proliferator-activated receptor γ (PPARγ) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 278:962–967CrossRefPubMed Dang C-C, Audinot V, Papapoulos SE, Boutin JA, Löwik CWGM (2003) Peroxisome proliferator-activated receptor γ (PPARγ) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 278:962–967CrossRefPubMed
77.
go back to reference Solimini NL, Luo J, Elledge SJ (2007) Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130:986–988CrossRefPubMed Solimini NL, Luo J, Elledge SJ (2007) Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130:986–988CrossRefPubMed
Metadata
Title
The Role of Sex Steroid Receptors on Lipogenesis in Breast and Prostate Carcinogenesis: A Viewpoint
Authors
Henri Rochefort
Dany Chalbos
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Discover Oncology / Issue 2/2010
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-010-0009-7

Other articles of this Issue 2/2010

Discover Oncology 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.